Release Date: January 31, 2023
Expiration Date: January 31, 2024
 

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives
After participating in this activity, participants should be better able to:

• Evaluate the safety and efficacy of currently approved BTK inhibitors for patients with hematologic malignancies, including CLL/SLL, lymphoma, and Waldenström’s macroglobulinemia 
• Review clinical trial results of emerging BTK-inhibitor-based strategies that are being investigated in patients with hematologic malignancies
• Compare and contrast the safety and efficacy of BTK inhibitors in order to properly select and sequence this class of agents in patients with newly diagnosed and relapsed/refractory hematologic malignancies

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Module 1: Ibrutinib for Hematologic Malignancies
• Module 2: Acalabrutinib for Hematologic Malignancies
• Module 3: Zanubrutinib for Hematologic Malignancies
• Module 4: Emerging BTK Inhibitors
• Module 5: Experts Debate Optimal Selection and Sequencing Strategies

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Matthew Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.​

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Grants/Research Support: LOXO/Lilly and AbbVie, Paid to institution

Speakers Bureau/Honoraria for non-CME: Genentech, AbbVie, AstraZeneca, Beigene, LOXO/Lilly

Consultant/Advisory Board: Genentech, AbbVie, AstraZeneca, Beigene, LOXO/Lilly, TG Therapeutics, MEI Pharma, Octapharma, Janssen

Non-Mutual funds Stock Ownership/Stock options: CTI Biopharma, Bluebird Bio

Anthony Mato, MD, MSCE­
Medical Oncologist/CLL Specialist­
New York, New York

­Grants/Research Support: AbbVie, Genentech, LOXO, DTRM, Genmab, AZ, Beigene, Nurix, Pharmacyclics

Consultant/Advisory Board: Abbvie, Genentech, LOXO, DTRM, Genmab, AZ, Beigene, Nurix, Pharmacyclics

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Support
This activity is supported by an independent educational grant from AstraZeneca

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.